Exenatide Once Monthly Showed Positive Results In Phase 2 Study
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes. The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three …
Read more on Medical News Today
Related posts:
- Monthly B12 Injection Created on October 15, 2011 using FlipShare. I have...
- 11 Tips to Detoxify your Body and Mind and Engender Positive Emotions www.cosmic-joy.com 1) Reversing Damage – Years of stressful living...
Related posts brought to you by Yet Another Related Posts Plugin.